Nanobiotix S.A. — Form 6-K Summary
Business Context and Reporting Period
Nanobiotix S.A., a French foreign private issuer, filed Form 6-K for June 2024. The filing reports that the company issued a press release on June 2, 2024, incorporated as Exhibit 99.1. The filing identifies the company’s principal executive office as 60 Rue de Wattignies, Paris, France.
Financial Metrics
The filing text provided does not include revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics. The referenced June 2, 2024 press release is not included in the supplied text.
Material Changes Versus Prior Period
The supplied filing text does not describe material changes versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not provide guidance, outlook, management commentary, risk disclosures, contingencies, or unusual items. Any such information may be contained in Exhibit 99.1, which is referenced but not reproduced.
Important Facts to Verify
- Obtain and review Exhibit 99.1, the June 2, 2024 press release.
- Verify whether the press release contains operating or financial updates, clinical-development information, financing activity, or revised outlook.
- Confirm any reported cash runway, capital needs, debt obligations, or other liquidity information in the underlying exhibit.
- Note that this Form 6-K was signed on June 2, 2024 by Bart Van Rhijn, Chief Financial Officer.